Paricalcitol
- Generic Name
- Paricalcitol
- Brand Names
- Zemplar
- Drug Type
- Small Molecule
- Chemical Formula
- C27H44O3
- CAS Number
- 131918-61-1
- Unique Ingredient Identifier
- 6702D36OG5
- Background
Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.
- Indication
For treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and 4
- Associated Conditions
- Secondary Hyperparathyroidism (SHPT)
- Associated Therapies
- -
A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 3
- Registration Number
- NCT03300921
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2016-10-12
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT02930902
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Paricalcitol Improves Anemia of Inflammation
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Hospital Son Espases
- Target Recruit Count
- 19
- Registration Number
- NCT02876211
- Locations
- 🇪🇸
Son Espases University Hospital, Palma de Mallorca, Islas Baleares, Spain
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2016-04-28
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- HonorHealth Research Institute
- Target Recruit Count
- 35
- Registration Number
- NCT02754726
- Locations
- 🇺🇸
Clinical Trials Nurse Navigator, Scottsdale, Arizona, United States
DBPC-Dose-finding-trial of Vitamin D3 for SCIT in Birch Pollen Allergic Patients.
- Conditions
- Interventions
- First Posted Date
- 2016-02-22
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Laurian Jongejan
- Target Recruit Count
- 44
- Registration Number
- NCT02686827
- Locations
- 🇳🇱
Academic medical center, Amsterdam, Netherlands
European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2022-05-24
- Lead Sponsor
- University Hospital Goettingen
- Target Recruit Count
- 500
- Registration Number
- NCT02378805
- Locations
- 🇩🇪
University Hospital Goettingen, Goettingen, Germany
Effect of Paricalcitol Over Vessel Wall
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2015-02-26
- Lead Sponsor
- Effice Servicios Para la Investigacion S.L.
- Target Recruit Count
- 50
- Registration Number
- NCT02372695
Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002
- Conditions
- Interventions
- First Posted Date
- 2014-11-04
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- OPKO Health, Inc.
- Target Recruit Count
- 298
- Registration Number
- NCT02282813
Paricalcitol in Fabry Disease
- First Posted Date
- 2014-03-18
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Federico II University
- Target Recruit Count
- 14
- Registration Number
- NCT02090608
- Locations
- 🇮🇹
federico II university, department of nephrology, Naples, Italy
A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2024-02-13
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 15
- Registration Number
- NCT02030860
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.